Content
April 2000, Volume 17, Issue 4
- 351-360 Potential Savings in the Cost of Caring for Alzheimer’s Disease
by A. Hauber & Ari Gnanasakthy & Edward Snyder & Mohan Bala & Anke Richter & Josephine Mauskopf - 361-370 Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy
by Mark Sculpher & Michael Palmer & Anne Heyes - 371-382 Initial Treatment Choice in Depression
by Eric Edgell & Timothy Hylan & JoLaine Draugalis & Stephen Coons - 383-389 Cost Analysis of the Treatment of Schizophrenia in the UK
by Stephen Almond & Owen O’Donnell - 391-401 Cost Effectiveness of Competing Strategies to Prevent or Treat GORD-Related Dysphagia
by Amnon Sonnenberg
December 1998, Volume 14, Issue 6
- 597-601 Are Mental Health Services Losing Out in the US Under Managed Care?
by Dale Johnson - 603-611 Thrombolysis, Stroke Units and Other Strategies for Reducing Acute Stroke Costs
by Theodore Wein & Susan Hickenbottom & Andrei Alexandrov - 613-627 A Review of Quality of Life in Alzheimer’s Disease
by Sam Salek & Melvyn Walker & Antony Bayer - 629-637 Insomnia, Health-Related Quality of Life and Healthcare Resource Consumption
by Hind Hatoum & Sheldon Kong & Christopher Kania & Josephine Wong & Wallace Mendelson - 639-652 The Use and Cost of HIV Service Provision in England in 1996
by Eduard Beck & Keith Tolley & Amanda Power & Sundhiya Mandalia & Philippa Rutter & Junichi Izumi & Jeni Beecham & Alistair Gray & David Barlow & Philippa Easterbrook & Martin Fisher & John Innes & George Kinghorn & Bibhat Mandel & Anton Pozniak & Allan Tang & David Tomlinson & Ian Williams - 653-669 Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction
by Peter Schädlich & Eduard Huppertz & Josef Brecht - 671-684 Cost-Effectiveness Analysis of Formoterol Versus Salmeterol in Patients with Asthma
by Maureen Mölken & Eddy Doorslaer & M. Till - 685-690 Fosphenytoin
by Stephen Holliday & Paul Benfield & Greg Plosker - 691-708 Cyclosporin Microemulsion (Neoral®)†
by Allan Coukell & Greg Plosker - 709-709 A Short Term Cost-Effectiveness Model for Oral Antidiabetic Medicines in Europe
by Linda MacKeigan - 710-711 The authors reply
by Sheila Hood & Lieven Annemans & Maureen Mölken - 711-712 Common Errors and Controversies in Pharmacoeconomic Analyses
by Javier Soto
June 1997, Volume 11, Issue 6
- 594-594 Erratum to Will Managed Care Work in Europe?
by E. Mossialos & P. Kanavos & B. Abel-Smith
March 1997, Volume 11, Issue 3
- 286-286 Erratum to Rational prescribing of antibacterials in ambulatory children
by JE Hoppe
February 1997, Volume 11, Issue 2
- 115-118 Economic Evaluation Techniques in Healthcare
by Alan Maynard - 119-125 The Role of the US Food and Drug Administration’s Patient Information Initiative in Cost-Effective Drug Therapy
by Stuart Nightingale & Thomas McGinnis - 126-138 The Economics of Osteoporosis and Its Prevention
by David Torgerson & David Reid - 139-158 The Economics of Pharmacotherapy for Diabetes Mellitus
by Bernardo Costa & Jaume Arroyo & Angels Sabaté - 159-168 Guidelines for Pharmacoeconomic Studies
by Joanna Siegel & George Torrance & Louise Russell & Bryan Luce & Milton Weinstein & Marthe Gold - 169-174 An Economic Evaluation of the Use of Granulocyte Colony-Stimulating Factor After Bone Marrow Transplantation in Children
by Nicholas Duncan & Margaret Hewetson & Ayad Atra & Gina Dick & Ross Pinkerton - 175-183 Differences in the Methodology and Data of Economic Evaluations of a Health Programme
by Xavier Badia & Gonzalo Nocea & Joan Rovira - 184-197 Terazosin
by Greg Plosker & Karen Goa